Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

Table 5 Effect of tolvaptan 60 mg at baseline, during, and after systemic inhibition of NO synthesis on brachial systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

Periods	Baseline	L-NMMA		Post infusion		p (GLM-within)
Periods	Prior to L-NMMA infusion	At the beginning of infusion	At the end of infusion	30 min after the end of L-NMMA infusion	60 min after the end of L-NMMA infusion	p (GLM-within)
SBP (mmHG)
Placebo	137 ± 12	146 ± 17	149 ± 16	147 ± 16	146 ± 13	0.407
Tolvaptan 60 mg	135 ± 9	144 ± 15	144 ± 14	142 ± 15	144 ± 13	0.407
p (GLM between)	0.305
p (paired t-test, between)	0.276	0.623	0.107	0.134	0.332
DBP (mmHg)
Placebo	82 ± 10	88 ± 11	90 ± 10	87 ± 9	87 ± 9	0.502
Tolvaptan 60 mg	81 ± 8	88 ± 9	87 ± 9	85 ± 8	85 ± 8	0.502
p (GLM between)	0.659
p (paired t-test, between)	0.410	0.762	0.094	0.101	0.190
Pulse rate (BPM)
Placebo	58 ± 9	55 ± 8	55 ± 9	56 ± 9	6 0 ± 10	0.319
Tolvaptan 60 mg	58 ± 9	54 ± 9	54 ± 9	57 ± 10	60 ± 11	0.319
p (GLM between)	0.991
p (paired t-test, between)	0.699	0.431	0.502	0.873	0.966

Data are given as mean ± SD. General linear model (GLM) with repeated measures was performed for comparison within and between treatment groups. Post-hoc Bonferoni test was used for comparison between L-NMMA infusion period (at the beginning/ at the end of L-NMMA infusion period) vs baseline (prior to L-NMMA infusion period) and baseline vs post infusion period (30 min/60 min after the end of L-NMMA infusion) vs baseline, none of the p- values were significant. Paired t-test was used for comparison between treatment groups

ISSN: 1471-2369